Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development

Author： Barry Evan R   Corry Gareth N   Rasmussen Theodore P  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.14, Iss.4, 2010-04, pp. : 405-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects

By  

Current Medicinal Chemistry, Vol. 11, Iss. 16, 2004-08 ,pp. : 2161-2183

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein

By  

Current Medicinal Chemistry, Vol. 24, Iss. 40, 2018-01 ,pp. : 4488-4514

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO

By  

Current Drug Targets, Vol. 11, Iss. 9, 2010-01 ,pp. : 1181-1191

Bentham Science Publishers

Access to resources Recommend Favorite

Pleiotropic Role of HSF1 in Neoplastic Transformation

By  

Current Cancer Drug Targets, Vol. 14, Iss. 2, 2014-02 ,pp. : 144-155

Bentham Science Publishers

Access to resources Recommend Favorite

The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 5, 2006-07 ,pp. : 323-329

Bentham Science Publishers

Access to resources Recommend Favorite